Salvage therapies including retreatment with BCMA|directed ...

Salvage therapies including retreatment with BCMA-directed ...

Retreatment with BCMA-directed CAR-T and BsAbs can be effective salvage options after BCMA-directed CAR-T relapse; however, DORs appear limited.

Salvage therapies including retreatment with BCMA-directed ...

For patients with relapsed/refractory multiple myeloma with a relapse after B-cell maturation antigen (BCMA)-directed chimeric antigen ...

Salvage therapies including retreatment with BCMA-directed ...

Retreatment with BCMA-directed CAR-T and BsAbs can be effective salvage options after BCMA-directed CAR-T relapse; however, DORs appear limited.

Salvage therapies including retreatment with BCMA-directed ...

The overall response rate for firstline salvage therapy was 41% (95% CI, 28-55). ... Retreatment with BCMA-directed CAR-T and BsAbs can be ...

Interventions and outcomes of patients with multiple myeloma ...

In a cohort of 79 patients relapsing after BCMA-directed CAR T, multiple lines of salvage therapy led to a median overall survival of 17.9 months.

Salvage Therapies including Retreatment with BCMA-directed ...

Salvage Therapies including Retreatment with BCMA-directed Approaches Following BCMA CAR-T Relapses for. For patients with relapsed ...

Mechanisms and salvage treatments in patients with multiple ...

In recent years, some academic institutions have achieved certain results in salvage treatments of patients with relapse after BCMA CAR-T treatment through ...

Salvage Therapies including Retreatment with BCMA-directed ...

The overall response rate for first-line salvage therapy was 41% (CI: 28-55%). ... Retreatment with BCMA-directed CAR-T and BsAb can be effective ...

Salvage Therapies including Retreatment with BCMA-directed ...

Retreatment with BCMA-directed CAR-T and BsAb can be effective salvage options post-BCMA-directed CAR-T relapse; however, DORs appear limited and further ...

Salvage therapy hope after CAR T relapse for multiple myeloma

... including bispecific antibodies and other types of CAR-T cell therapy. ... salvage treatment after BCMA-directed CAR T therapy.” Blood, doi ...

Clinical features associated with poor response and early relapse ...

Clinical trial and real-world data indicate the first BCMA-directed treatment is the most effective, and that CAR-T outcomes are most ...

CAR T-Cell Therapy Can Work as Salvage Treatment in Relapsed ...

People with multiple myeloma (MM) who relapse following treatment with B-cell maturation antigen (BCMA)-directed chimeric antigen receptor ...

Outcomes With Salvage Therapies in RRMM Post-CAR T Relapse ...

With salvage therapy a BCMA bispecific (n = 5), the ORR was 60% and the median duration of treatment was 1.6 months. Anti-CD38 salvage therapy ( ...

Salvage therapies including retreatment with BCMA-directed ... - OUCI

Abstract For patients with relapsed/refractory multiple myeloma with a relapse after B-cell maturation antigen (BCMA)–directed chimeric antigen receptor ...

Salvage therapies including retreatment with BCMA-directed ...

Dive into the research topics of 'Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma'.

Novel Therapies in BCMA-exposed Relapsed/Refractory Multiple ...

One possible BCMA-targeted re-challenging treatment could include the use of daratumumab. Daratumumab is a human monoclonal antibody that binds ...

Sequencing Immunotherapy for Multiple Myeloma

Sequential use of bsAb therapy has been reported in a cohort of 58 patients who relapsed after treatment with a bsAb on a clinical trial (BCMA- ...

Outcomes in patients with multiple myeloma receiving salvage ...

In our study, 32 patients received the first salvage treatment, including PI-based combination therapy, another BCMA CAR-T or combination ...

(PDF) Mechanisms and salvage treatments in patients with multiple ...

In recent years, some academic institutions have achieved certain results in salvage treatments of patients with relapse after BCMA CAR-T ...

Strategies for Salvage Therapy Post CAR-T Therapy Failure in ...

The NCCN 2024 V2 guidelines recommend combination regimens as the prior-line treatment, including proteasome inhibitors (or CD38 monoclonal ...